12:00 AM
 | 
Jan 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Androxal enclomiphene: Phase IIb data

Top-line data from the double-blind, U.S. Phase IIb ZA-203 trial in 108 men less than 65 years of age who were naïve to testosterone therapy and who had morning testosterone levels of <250 ng/dL showed that once-daily 12.5 and 25 mg Androxal significantly increased median morning testosterone levels from baseline to 3 months vs. placebo. Specifically, low- and high-dose Androxal increased median morning testosterone...

Read the full 298 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >